CRISPR Editing Human Primary Resting CD4+ T Cells with RNPs using Nucleofector® Technology
Learn how Synthego’s proprietary synthetic sgRNA helped achieve high-efficiency editing in resting human CD4+ T cells in conjunction with Lonza’s 4D-NucleofectorⓇ
Primary cells are often challenging to edit and transfect, limiting long-term viabilities, editing efficiencies, and downstream functional assays, despite their tremendous value in translational research. This protocol, developed in collaboration with Lonza, describes step-by-step instructions on editing resting primary human CD4+ T cells using Synthego’s synthetic sgRNA and Lonza 4D-Nucleofector®.
Although primary cells can be challenging to transfect and manipulate, Synthego’s chemically modified synthetic sgRNAs are of exceptional purity and consistently drive high editing frequencies.
This protocol describes the step-by-step process of transfecting and culturing resting human primary CD4+ T cells under optimal conditions.
- Required transfection reagents and equipment
- Detailed transfection protocols, including steps on how to use the Lonza 4D-Nucleofector®
- Data that demonstrate editing efficiency in resting human primary CD4+ T cells